Blogs | MedChemExpress

DCH36_06 is a Selective p300/CBP Inhibitor

DCH36_06 is a potent and selective p300/CBP inhibitor with strong anti-tumor activities both in vivo and in vitro.
UK122 is a Selective Urokinase-Type Plasminogen Activator (uPA) Inhibitor

UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
Pelcitoclax (APG-1252) is a Bcl-2/Bcl-xl Inhibitor with Antineoplastic and Pro-Apoptotic Effects

Pelcitoclax has potent anti-tumor effects through ntrinsic mitochondrial pathway of apoptosis in cancer cells.
Nimotuzumab is a Humanized IgG1 Monoclonal Antibody Targeting EGFR

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR. Nimotuzumab is a strong antitumor drug.
XY028-140 is a Selective CDK4 and CDK6 PROTAC Degrader

XY028-140 is a potent and selective PROTAC-based CDK4/6 degrader, which can inhibit RB-E2F signaling and reduce CDK4 and CDK6 protein levels.
GGTI-2154 is a Selective Geranylgeranyltransferase I (GGTase I) Inhibitor

GGTI-2154 is a potent and selective inhibitor of GGTase I and has the potential for the research of cancer.
Inupadenant is an Orally Active and Highly Selective A2A Receptor Antagonist

Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
ABBV-744 is a First-in-Class, Orally Active and Selective BET BDII Inhibitor

ABBV-744 is a first-in-class, orally active and selective BET BDII inhibitor could provide an effective study for prostate cancer.
DP-C-4 is a CRBN-Based dual PROTAC for EGFR and PARP

DP-C-4 is a CRBN-Based dual PROTAC for EGFR and PARP could provide an effective study for cancer diseases.
SJ6986 is a Selective and Orally Active GSPT1/2 Degrader

SJ6986 is a selective and orally active GSPT1/GSPT2 degrader, displaying selectivity over classical IMiD neosubstrates, such as IKZF1/3

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (19)